PSMD is a new, fully automated, and robust imaging marker for SVD. 3 key findings →
Design: longitudinal study Participants: 113 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Research
27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Cognitive activity participation is associated with lower risk of development of amnestic mild cognitive impairment, even after excluding individuals at early stages of dementia. 4 key findings →
Design: prospective cohort Participants: 58 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In most of the decedents, the course of disability in the last year of life did not follow a predictable pattern based on the condition leading to death. 1 key finding →
Design: longitudinal study Participants: 65 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Individuals with AD comprise a substantial number of older adult deaths in the United States, a number expected to rise considerably in coming decades. 1 key finding →
Design: longitudinal study Participants: 10,802 Evidence: moderate
Full summary, score breakdown and related studies → Original source
67/100
The findings of this study suggest an increased risk of dementia among individuals with TBI. 3 key findings →
Design: cohort study Participants: 44,925 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our results support an association between the use of ADT in the treatment of prostate cancer and an increased risk of Alzheimer's disease in a general population cohort. 4 key findings →
Design: retrospective cohort Participants: 16,888 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Androgen deprivation therapy in the treatment of prostate cancer may be associated with an increased risk of dementia. 5 key findings →
Design: cohort study Participants: 9,455 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among older Medicare beneficiaries with heart failure, there is a higher overall burden of comorbidity and greater prevalence of discordant comorbidity among the oldest old. 5 key findings →
Design: cohort study Participants: 201,130 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dialysis modality is associated with incident dementia in a cohort of older ESRD patients. 4 key findings →
Design: cohort study Participants: 121,623 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Dual-eligible older persons are at greater risk for decline in function and cognition after an ICU hospitalization than their more advantaged counterparts. 2 key findings →
Design: cohort study Participants: 641 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Pioglitazone is a time- and dose-dependent protective factor against dementia in patients with diabetes. 2 key findings →
Design: cohort study Participants: 6,401 Evidence: moderate
Full summary, score breakdown and related studies → Original source
67/100
Dementia is among various diseases affecting the elderly, who is also at a high risk for fractures. 3 key findings →
Design: cohort study Participants: 66,797 Evidence: moderate
Full summary, score breakdown and related studies → Original source
67/100
Deintensification of treatment regimens occurred in less than one-half of potentially overtreated Veterans and was more strongly associated with low HbA1c values and use of medications with high risk for hypoglycemia, rather than other resident characteristics. 5 key findings →
Design: cohort study Participants: 3,056 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Principal component analysis identified patterns of variation in baseline and longitudinal measures of tau uptake and volume that were significantly different across phenotypes. 2 key findings →
Design: longitudinal study Participants: 57 Evidence: moderate
Full summary, score breakdown and related studies → Original source
67/100
At 20 months 12.3% of the MCI group progressed to dementia, 62.9% continued to meet MCI criteria, and 24.7% reverted to unimpaired levels of function. 5 key findings →
Design: longitudinal study Participants: 106 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In covariate-adjusted intent-to-treat analyses, haloperidol was associated with the highest mortality rates (relative risk=1.54, 95% confidence interval [CI]=1.38-1.73) followed by risperidone (reference), olanzapine (relative risk=0.99, 95% CI=0.89-1.10), valproic acid and its derivatives (relative risk=0.91, 95% CI=0.78-1.06), and quetiapine (relative risk=0.73, 95% CI=0.67-0.80). 5 key findings →
Design: cohort study Participants: 33,604 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A biomarker panel was identified that included markers significantly increased (cortisol, pancreatic polypeptide, insulinlike growth factor binding protein 2, β(2) microglobulin, vascular cell adhesion molecule 1, carcinoembryonic antigen, matrix metalloprotein 2, CD40, macrophage inflammatory protein 1α, superoxide dismutase, and homocysteine) and decreased (apolipoprotein E, epidermal growth factor receptor, hemoglobin, calcium, zinc, interleukin 17, and albumin) in AD. 5 key findings →
Design: longitudinal study Participants: 207 Evidence: moderate
Full summary, score breakdown and related studies → Original source
67/100
Alzheimer's disease has a long asymptomatic phase that offers a substantial time window for intervention. 2 key findings →
Design: longitudinal study Participants: 410 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Plasma p-tau181 is elevated in patients with ALS, independently from CSF levels, and is firmly associated with LMN dysfunction. 5 key findings →
Design: longitudinal study Participants: 39 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In the CU, amyloid-negative (A-) subset, plasma p-tau217 levels increased modestly with age but were unaffected by body mass index and kidney function. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Baseline CSF Aβ42/Aβ40 ratio was decreased in MCI and AD compared to CN, while CSF p-tau181 and t-tau increased. 3 key findings →
Design: longitudinal study Participants: 430 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study will establish the precision of TAS Test to identify preclinical AD and estimate risk of cognitive decline and AD. 2 key findings →
Design: cohort study Participants: 300 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Cross-sectionally, CSF sTREM2, YKL-40, clusterin and fractalkine were higher only in groups with tau pathology, independent of amyloidosis (p < 0.001, A+/T+ or N+ and A-/T+ or N+, compared to A-/T-/N-). 5 key findings →
Design: cohort study Participants: 535 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Using nearly 8,000 British civil servants followed for up to 25 years (the Whitehall II study), this study found that people who slept 6 hours or less per night in their 50s and 60s had a higher later risk of dementia than those sleeping about 7 hours, even after accounting for other health and social factors. 4 key findings →
Design: cohort Participants: 7,959 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This prospective study followed 392 older spousal caregivers and 427 non-caregivers for an average of 4.5 years. 3 key findings →
Design: cohort Participants: 819 Evidence: high
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →